Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Multicentre, Phase Ib/II Study of MEN1611, a PI3K Inhibitor, and Cetuximab in Patients With PIK3CA Mutated Metastatic Colorectal Cancer Failing Irinotecan, Oxaliplatin, 5-FU and Anti-EGFR Containing Regimens

NCT04495621 is registered in ClinicalTrials.gov with Menarini Group as lead sponsor.

NCT NCT04495621
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04495621 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Multicentre, Phase Ib/II Study of MEN1611, a PI3K Inhibitor, and Cetuximab in Patients With PIK3CA Mutated Metastatic Colorectal Cancer Failing Irinotecan, Oxaliplatin, 5-FU and Anti-EGFR Containing Regimens
Lead sponsor
Menarini Group
Phase
Phase 1/2
Overall status
Completed
Start date
July 20, 2020
Completion date
February 27, 2024
Enrollment
29 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer